Young Lung Cancer Investigator Awarded a $200,000 Grant to Support Research in Translational Immuno-oncology streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
WALNUT CREEK, Calif. - March 21, 2022 - (Newswire.com) Vivacitas Oncology, Inc. ("Vivacitas" or the "Company"), a privately-held oncology company focused on tough-to-treat cancers, is honored to welcome, Dr. David Reardon, MD, Professor of Medicine at Harvard Medical School and Clin.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstracts at American .
Provectus Biopharmaceuticals Inc.April 28, 2021 GMT Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors ( NCT0269367 ) Systemic administration of PV-10 for treatment of solid tumor cancers
KNOXVILLE, TN, April 28, 2021 (GLOBE NEWSWIRE) Provectus (OTCQB: PVCT) today announced that two abstracts about data from clinical and preclinical study of investigational cancer immunotherapy PV-10 (rose bengal disodium) were accepted for the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, which will be held June 4-8 online.